The pastry chef who patented an anti-cancer molecule that's been bought for over $8 billion
Petosemtamab, co-invented by Eduard Batlle, achieved high response rates and complete remissions in head and neck cancer trials and was sold to Genmab.
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Amivantamab injections rapidly shrank tumours in recurrent or metastatic head and neck squamous cell carcinoma patients within six weeks in a multinational trial.